Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 7
2007 2
2008 3
2009 3
2010 9
2011 5
2012 7
2013 11
2014 21
2015 66
2016 175
2017 295
2018 324
2019 401
2020 498
2021 609
2022 628
2023 660
2024 719
2025 846
2026 590

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,023 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean psm pet prostate cancer (5 results)?
PSMA PET imaging in the diagnosis and management of prostate cancer.
Houshmand S, Lawhn-Heath C, Behr S. Houshmand S, et al. Abdom Radiol (NY). 2023 Dec;48(12):3610-3623. doi: 10.1007/s00261-023-04002-z. Epub 2023 Jul 26. Abdom Radiol (NY). 2023. PMID: 37493837 Free PMC article. Review.
In this review we will explore the role of PSMA PET in high-risk prostate cancer staging, biochemical recurrence, and castration-resistant prostate cancer. ...In addition, we will touch upon the potential future advancements of PSMA …
In this review we will explore the role of PSMA PET in high-risk prostate cancer staging, biochemical recurrence …
PSMA PET/CT in the diagnosis of prostate cancer: why and when?
Pepe P, Pepe L, Cignoli D, Roscigno M. Pepe P, et al. Arch Ital Urol Androl. 2025 Jun 30;97(2):13746. doi: 10.4081/aiua.2025.13746. Epub 2025 May 15. Arch Ital Urol Androl. 2025. PMID: 40372183 Free article. Review.
Prostate-specific membrane antigen (PSMA) is expressed in most primitive and metastatic prostate cancer (PCa), and PSMA inhibitors conjugated with the radionuclides Gallium 68 (68Ga) and fluoride 18 (18F) have been evaluated to detect PCa; moreo …
Prostate-specific membrane antigen (PSMA) is expressed in most primitive and metastatic prostate cancer (PCa), a …
PSMA PET/CT for prostate cancer diagnosis: current applications and future directions.
Shen Z, Li Z, Li Y, Tang X, Lu J, Chen L, Cheng ZZ, Liao H, Zhou S. Shen Z, et al. J Cancer Res Clin Oncol. 2025 May 4;151(5):155. doi: 10.1007/s00432-025-06184-z. J Cancer Res Clin Oncol. 2025. PMID: 40319443 Free PMC article. Review.
Prostate cancer (PCa) requires improved diagnostic strategies beyond conventional imaging. ...In BCR cases, PSMA PET/CT reliably detected recurrent lesions at low prostate-specific antigen levels, significantly influencing treatment strategies. …
Prostate cancer (PCa) requires improved diagnostic strategies beyond conventional imaging. ...In BCR cases, PSMA PET …
Prostate Cancer Theranostics: PSMA Targeted Therapy.
Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Seifert R, et al. PET Clin. 2021 Jul;16(3):391-396. doi: 10.1016/j.cpet.2021.03.004. PET Clin. 2021. PMID: 34053583 Review.
Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, …
Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targ …
225Ac-PSMA-617 for PSMA-Targeted alpha-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, Kopka K, Apostolidis C, Haberkorn U, Morgenstern A. Kratochwil C, et al. J Nucl Med. 2016 Dec;57(12):1941-1944. doi: 10.2967/jnumed.116.178673. Epub 2016 Jul 7. J Nucl Med. 2016. PMID: 27390158 Free article.
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an alpha-radionuclide-labeled PSMA ligand. ...CONCLUSION: Targeted alpha-therapy with (225)Ac-PSMA- …
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the fir …
Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT.
Gafita A, Schroeder JA, Ceci F, Oldan JD, Khandani AH, Lecouvet FE, Solnes LB, Rowe SP. Gafita A, et al. J Nucl Med. 2025 Jul 1;66(7):995-1004. doi: 10.2967/jnumed.124.268071. J Nucl Med. 2025. PMID: 40473460 Free article. Review.
In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)-targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there have been regulatory approvals for PSMA …
In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)-targeted PET …
Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2).
Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, Giesel FL, Reiter R, Maurer T, Heck M, Gafita A, Morris MJ, Fanti S, Weber WA, Hope TA, Hofman MS, Fendler WP, Eiber M. Seifert R, et al. Eur Urol. 2023 May;83(5):405-412. doi: 10.1016/j.eururo.2023.02.002. Epub 2023 Mar 17. Eur Urol. 2023. PMID: 36935345 Free article. Review.
CONTEXT: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a reference imaging tool for the staging and restaging of patients with prostate cancer for both clinical routine and trials. T …
CONTEXT: Prostate-specific membrane antigen (PSMA) targeting positron emission tomography (PET) is emerging to become a …
PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.
Eapen RS, Nzenza TC, Murphy DG, Hofman MS, Cooperberg M, Lawrentschuk N. Eapen RS, et al. World J Urol. 2019 Jul;37(7):1255-1261. doi: 10.1007/s00345-018-2524-z. Epub 2018 Oct 29. World J Urol. 2019. PMID: 30374609 Review.
This gap is now being filled by PSMA PET. PSMA PET scans have now been shown to have a role in all stages in the prostate cancer journey. ...In this paper, we review the evidence for the use of PSMA PET in the various stages …
This gap is now being filled by PSMA PET. PSMA PET scans have now been shown to have a role in all stages in the …
The Impact of PSMA PET/CT Imaging in Prostate Cancer Radiation Treatment.
Mena E, Lindenberg L, Choyke P. Mena E, et al. Semin Nucl Med. 2022 Mar;52(2):255-262. doi: 10.1053/j.semnuclmed.2021.12.008. Epub 2022 Jan 10. Semin Nucl Med. 2022. PMID: 35016755 Free PMC article. Review.
Imaging of prostate cancer is rapidly evolving with the introduction of the novel prostate-specific membrane antigen (PSMA)-targeted PET imaging tool for managing recurrent prostate cancer. ...The aim of the review is to give an ov …
Imaging of prostate cancer is rapidly evolving with the introduction of the novel prostate-specific membrane antigen ( …
PSMA Ligands for PET Imaging of Prostate Cancer.
Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, Afshar-Oromieh A, Herrmann K, Eiber M. Schwarzenboeck SM, et al. J Nucl Med. 2017 Oct;58(10):1545-1552. doi: 10.2967/jnumed.117.191031. Epub 2017 Jul 7. J Nucl Med. 2017. PMID: 28687599 Free article. Review.
Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-labeled and (18)F-labeled PET agents has become increasingly important in recent years. Imaging of biochemically recurrent prostate cancer has been established as a widely accep …
Targeting the prostate-specific membrane antigen (PSMA) with (68)Ga-labeled and (18)F-labeled PET agents has become inc …
5,023 results